Real world study on the treatment of spinal degenerative axial pain with Ruyi Zhenbao tablets

Application of Ruyi Zhenbao tablets in the treatment of degenerative axial pain of the spine based on the theory of "white vein" disease - A randomized, parallel controlled real world study

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

ITMCTR

Registry ID

ITMCTR2024000243

Enrollment

Unknown

Registered

2024-08-15

Start date

2024-09-01

Completion date

Unknown

Last updated

2024-09-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

degenerative axial pain of the spine

Interventions

observation group :On the basis of conventional treatment, receive oral treatment with Ruyi Zhenbao tablets (Qizheng, specification 0.5g/tablet), 5 tablets each time, twice a day, for a course of 4 we

control group:Regular treatment: oral non steroidal anti-inflammatory drugs, muscle relaxants, neurotrophic drugs and other drugs, which can be combined with plaster application, acupuncture and moxib

Eligibility

Sex/Gender

All

Age

12 Years to 120 Years

Inclusion criteria

Inclusion criteria: 1) Axial pain originates from degenerative changes in the spine, including common diseases such as discogenic back pain, intervertebral disc herniation with back pain, lumbar spondylolisthesis, lumbar scoliosis, facet joint disorder syndrome, cervical spondylosis, nerve root type cervical spondylosis with neck pain, thoracic scoliosis, osteoporotic vertebral body pain, and fixed sagittal plane imbalance Age = 12 years old; 3) Sign the informed consent form.

Exclusion criteria

Exclusion criteria: 1) Those who are allergic to the ingredients of Ruyi Treasure Tablets (Qizheng); 2) Complicated with spinal infectious diseases or tumor; 3) Pregnant or lactating women; 4) Professional athletes.

Design outcomes

Primary

Measure	Time frame
the MOS item short from health survey,SF36;visual analog scale;	—

Secondary

Measure	Time frame
surgical intervention rate;recurrence rate;	—

Countries

China

Contacts

Public ContactZ.H Yao

Tongxiang Traditional Chinese Medicine Hospital

495428526@qq.com+86 139 6738 4622

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Feb 4, 2026